ST3GAL1 and breast cancer: Authors reported that ST3GAL1 silencing reduces tumor growth with a remarkable decrease in vascularity of MCF7 xenografts and identified the angiogenin vasorin (VASN) as the main substrate of ST3GAL1 in breast cancer cells.